Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion
ROCKVILLE, Md., Sept. 22, 2026 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed the dose escalation portion of its ongoing Phase 1 clinical trial evaluating R-5780, the...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- WisdomAI and Teradata Partner to Deliver Agentic Intelligence for Mission-Critical Enterprise Data
- ATLANTIS PARADISE ISLAND WELCOMES 2027 WITH A STAR-STUDDED NEW YEAR'S CELEBRATION FEATURING MAESTRO ANDREA BOCELLI AND ALEX WARREN
- As Meditation Goes Mainstream, One Maker Rethinks Meditation Seats for Aging Bodies
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →